3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Solid Tumours
1
Sarcoma
1
Melanoma
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Interventions
Trabectedin
4
Doxorubicin
4
toripalimab
2
brigimadlin
2
belinostat
2
Fulvestrant
2
Dexamethasone
2
tanespimycin
1
soblidotin
1
siremadlin
1
selinexor
1
ridaforolimus
1
ribociclib
1
pembrolizumab
1
olaratumab
1
milademetan
1
enzalutamide
1
cemiplimab
1
atezolizumab
1
TTI-621
1
Sugars
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Letrozole
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liposarcoma
×
Famotidine
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled